Sigyn Therapeutics Q3 Earnings Report

Sigyn Therapeutics EPS Results

• Actual EPS: $0.49
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: $0.24

Sigyn Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Sigyn Therapeutics Announcement Details

• Quarter: Q3
• Date: 12/2/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Sigyn Therapeutics (OTCMKTS:SIGY), a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.